- Geranylgeraniol
-
- $30.00 / 50mg
-
2026-03-05
- CAS:24034-73-9
- Min. Order:
- Purity: 99.17%
- Supply Ability: 10g
- Geranylgeraniol
-
- $0.00 / 25KG
-
2025-12-01
- CAS:24034-73-9
- Min. Order: 1KG
- Purity: 95.0%
- Supply Ability: 10000KGS
- GERANYLGERANIOL
-
- $8.00 / 1KG
-
2025-09-25
- CAS:24034-73-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
| | GERANYLGERANIOL Basic information |
| Product Name: | GERANYLGERANIOL | | Synonyms: | Geranylgeraniol (Natural);GERANYLGERANIOL;Geranylgeraniol (mixture of isomers);2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-, (2E,6E,10E)-;(2E,6E,10E)-3,7,11,15-Tetramethyl-2,6,10,14-hexadecatetren-1-ol;(2E,6E,10E)-3,7,11,15-Tetramethylhexadecane-2,6,10,14-tetrene-1-ol;all-E-Geranylgeraniol;ALL TRANS-3,7,11,15-TETRAMETHYL-2,6,10,14-HEXADECATETRAEN-1-OL | | CAS: | 24034-73-9 | | MF: | C20H34O | | MW: | 290.48 | | EINECS: | | | Product Categories: | Miscellaneous Natural Products;Mixed Fatty Acids;Fatty Acid Derivatives & Lipids;Glycerols | | Mol File: | 24034-73-9.mol |  |
| | GERANYLGERANIOL Chemical Properties |
| Boiling point | 152-153 °C(Press: 0.07 Torr) | | density | 0.8930 g/cm3(Temp: 18 °C) | | storage temp. | -20°C | | solubility | Chloroform (Sparingly), Dichloromethane (Slightly), Ethyl Acetate (Slightly) | | pka | 14.42±0.10(Predicted) | | form | liquid | | color | Colourless to Light Yellow | | BRN | 1913779 | | Stability: | Light Sensistive, Temperature Sensitive | | Cosmetics Ingredients Functions | HUMECTANT
ANTIMICROBIAL
ANTIOXIDANT | | InChI | InChI=1S/C20H34O/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-21/h9,11,13,15,21H,6-8,10,12,14,16H2,1-5H3/b18-11+,19-13+,20-15+ | | InChIKey | OJISWRZIEWCUBN-QIRCYJPOSA-N | | SMILES | C(O)/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(/C)\C |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | HS Code | 29052290 | | Storage Class | 10 - Combustible liquids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | GERANYLGERANIOL Usage And Synthesis |
| Chemical Properties | Light Yellow Oil | | Uses | A intermediate in the lipidation of proteins, which plays a great importance for a variety of biological processes such as cell signalling | | Uses | Geranylgeraniol, a precursor to Geranylgeranylpyrophosphate (G367600), is an intermediate in the mevalonate pathway. Geranylgeraniol has been shown to prevent bone re-adsorption, inhibition of osteoclast formation, and kinase activation in vitro. | | Definition | ChEBI: Geranylgeraniol is a diterpenoid that is hexadeca-2,6,10,14-tetraene substituted by methyl groups at positions 3, 7, 11 and 15 and a hydroxy group at position 1. It has a role as a plant metabolite, a volatile oil component and an antileishmanial agent. It is a diterpenoid and a polyprenol. | | Biochem/physiol Actions | As the pyrophosphate, the metabolic precursor of all diterpenes. Screening in vitro shows this to be a potent and selective agent against Mycobacterium tuberculosis. | | in vivo | Geranylgeraniol (725 mg/kg/d; p.o.; 90 d) is not toxicologically significant with a dose below 725 mg/kg/d in rats[3].
Geranylgeraniol (483 mg/kg/d; p.o.; 10 d) suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats[4].
| Animal Model: | Han Wistar rats (169-192 g for male; 116-152 g for female)[3] | | Dosage: | 0, 725, 1450, and 2900 mg/kg | | Administration: | Oral gavage; once daily; 90 days | | Result: | Showed the lowest observed adverse effect level (LOAEL) for local effects and the no observed adverse effect level (NOAEL) for systemic effects as 725 mg/kg/d.
Reduced body weights by 12.9 and 21.6% in the intermediate- and high-dose group males, respectively, compared to controls. |
| Animal Model: | Wistar rats (male, 8-week-old, 130-150 g)[4] | | Dosage: | 0, 48.3, 483, 4830 mg/kg | | Administration: | Oral gavage; once daily; 10 days; with or not LPS challenge (i.p.; 0.5 mg/kg) | | Result: | Suppressed LPS-induced inflammatory cytokines and mRNA expression of LPS-induced inflammatory genes in liver with doses of 483 mg/kg and 4830 mg/kg.
Suppressed protein levels of IRAK1, TRAF6, and TAK1, originating from transcriptional down-regulation with doses of 483 mg/kg and 4830 mg/kg. |
|
| | GERANYLGERANIOL Preparation Products And Raw materials |
|